The role of epitope spreading in the pathology of relapsing-remitting experimental autoimmune encephalomyelitis (R-EAE) was examined. Using peripherally induced immunologic tolerance as a probe to analyze the neuropathologic T cell repertoire, we show that the majority of the immunopathologic reactivity during the acute phase of R-EAE in SJL/J mice induced by active immunization with the intact proteolipid (PLP) molecule is directed at the PLP139-151 epitope and that responses to secondary encephalitogenic PLP epitopes may contribute to the later relapsing phases of disease. Intermolecular epitope spreading was demonstrated by showing the development of T cell responses to PLP139-151 after acute disease in mice in which R-EAE was initiated by the transfer ofT cells specific for the non-cross-reactive MBP84-104 determinant. Intramolecular epitope spreading was demonstrated by showing that endogenous host T cells specific for a secondary encephalitogenic PLP epitope (PLP178-191) are demonstrable by both splenic T cell proliferative and in vivo delayed-type hypersensitivity responses in mice in which acute central nervous system damage was initiated by T cells reactive with the immunodominant, non-cross-reactive PLP139-151 sequence. The PLP178-191-specific responses are activated as a result of and correlate with the degree of acute tissue damage, since they do not develop in mice tolerized to the initiating epitope before expression of acute disease. Most importantly, we show that the PLP178-191-specific responses are capable of mediating R-EAE upon adoptive secondary transfer to naive recipient mice. Furthermore, induction of tolerance to intact PLP (which inhibits responses to both the initiating PLP139-151 epitope and to the PLP178-191 epitope) after the acute disease episode is sufficient to prevent relapsing disease. These results strongly support a contributory role ofT cell responses to epitopes released as a result of acute tissue damage to the immunopathogenesis of relapsing clinical episodes and have important implications for the design of antigenspecific immunotherapies for the treatment of chronic autoimmune disorders in humans. t~ lapsing experimental autoimmune encephalomyelitis (R-EAE) 1 is a CD4 + Thl-mediated demyelinating disease of the central nervous system (CNS) (1) that is inducible in genetically susceptible animals by immunization with myelin basic protein (MBP) or proteolipid protein (PLP) (2, 3) or synthetic peptides corresponding to the major encephalitogenic epitopes of MBP and PLP (4, 5). Alternatively, R-EAE The first two authors contributed equally to this work and should both be considered first authors.
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The role of epitope spreading in the pathology of relapsing-remitting experimental autoimmune encephalomyelitis (R-EAE) was examined. Using peripherally induced immunologic tolerance as a probe to analyze the neuropathologic T cell repertoire, we show that the majority of the immunopathologic reactivity during the acute phase of R-EAE in SJL/J mice induced by active immunization with the intact proteolipid (PLP) molecule is directed at the PLP139-151 epitope and that responses to secondary encephalitogenic PLP epitopes may contribute to the later relapsing phases of disease. Intermolecular epitope spreading was demonstrated by showing the development of T cell responses to PLP139-151 after acute disease in mice in which R-EAE was initiated by the transfer ofT cells specific for the non-cross-reactive MBP84-104 determinant. Intramolecular epitope spreading was demonstrated by showing that endogenous host T cells specific for a secondary encephalitogenic PLP epitope (PLP178-191) are demonstrable by both splenic T cell proliferative and in vivo delayed-type hypersensitivity responses in mice in which acute central nervous system damage was initiated by T cells reactive with the immunodominant, non-cross-reactive PLP139-151 sequence. The PLP178-191-specific responses are activated as a result of and correlate with the degree of acute tissue damage, since they do not develop in mice tolerized to the initiating epitope before expression of acute disease. Most importantly, we show that the PLP178-191-specific responses are capable of mediating R-EAE upon adoptive secondary transfer to naive recipient mice. Furthermore, induction of tolerance to intact PLP (which inhibits responses to both the initiating PLP139-151 epitope and to the PLP178-191 epitope) after the acute disease episode is sufficient to prevent relapsing disease. These results strongly support a contributory role ofT cell responses to epitopes released as a result of acute tissue damage to the immunopathogenesis of relapsing clinical episodes and have important implications for the design of antigenspecific immunotherapies for the treatment of chronic autoimmune disorders in humans. t~ lapsing experimental autoimmune encephalomyelitis (R-EAE) 1 is a CD4 + Thl-mediated demyelinating disease of the central nervous system (CNS) (1) that is inducible in genetically susceptible animals by immunization with myelin basic protein (MBP) or proteolipid protein (PLP) (2, 3) or synthetic peptides corresponding to the major encephalitogenic epitopes of MBP and PLP (4, 5). Alternatively, R-EAE The first two authors contributed equally to this work and should both be considered first authors.
1 Abbreviations used in this paper: CNS, central nervous system; DTH, delayed-type hypersensitivity; ECDI, 1-ethyl-3-(3-dimethylaminopropyl)-carhodiimide HC1; MBP, myelin basic protein; MMS, mean maximal disease severity; MS, multiple sclerosis; PLP, proteolipid protein; K-EAE, relapsing experimental autoimmune encephalomyelitis; SP, splenocyte. may be transferred to naive recipients with in vitro-activated MBP or PLP-specific CD4 + T cells (5-7). The relapsingremitting course of paralysis is characterized by a moderate to severe initial acute phase of disease followed by recovery and one or more relapses. This pattern of relapses and spontaneous recovery in experimental animal models, which occurs over a period of weeks to months, is very similar to the clinical signs of disease observed in multiple sclerosis (MS) patients over many years (8) .
The immunologic mechanisms involved in the induction and regulation of clinical relapses are unclear. Increased MHC class II expression has been found in the CNS of mice during clinical relapses (9, 10) and may influence the pattern of local production of pro-and antiinflammatory cytokines during relapses or remissions (11). Several studies have also demonstrated that changes occur in class II restriction and antigen specificity of neuroantigen-specific proliferative responses during the course of disease (12-15). Thus, reactivity to neuroepitopes other than that used to induce the initial clinical episode, a phenomenon termed epitope spreading (16) , may contribute to the relapsing course of clinical R-EAE. Epitope spreading has also recently been proposed to contribute to the pathogenesis of spontaneous autoimmune diabetes in the nonobese diabetic mouse (17, 18) . These reports provide intriguing evidence that the T cell repertoire is dynamic and that reactivity to additional specificities occurs during the course of both experimentally induced and spontaneous autoimmune diseases. This is of particular interest in MS, where B and T cell reactivity to MBP and PLP has been observed (19) (20) (21) . The broad spectrum of lymphocyte reactivity against CNS antigens in MS may result from diversification of antibody and T cell reactivities that occur as the myelin sheath suffers progressive damage. Epitope spreading could occur regardless of whether the initial inflammatory response in MS is due to direct reactivity against a CNS resident pathogen such as a virus (22) or to cross-reactivity between a pathogenencoded epitope and an epitope(s) on a myelin protein (16, 23) .
While T cell specificities appear to change over the course of R-EAE, the significance of these events in disease progression is not known. Relapses could result from activation of T cells specific for endogenous myelin epitopes released during the acute phase of disease. Proliferative responses to additional encephalitogenic myelin epitopes have been reported to arise after the initial acute phase of EAE (16, 24, 25) , but the functional consequences of these responses have not been addressed. In the current report, we demonstrate both intermolecular and intramolecular epitope spreading in two different models of myelin peptide-induced R-EAE. T cells reactive to a secondary encephalitogenic PLP epitope (PLP178-191) are found in the spleens of mice in which acute EAE was induced by T cells reactive with the dominant, non-cross-reactive PLP139-151 epitope. T cell responses specific for the secondary epitope are activated as a result of and correlate with the degree of acute CNS tissue damage. Most importantly, these T cells possess encephalitogenic potential in that they can initiate EAE upon secondary adoptive transfer to naive recipients. These results strongly support a role for intramolecular epitope spreading in the relapsing pathogenesis of PLP139-151-induced EAE. 151 or 100 #g of MBP84-104 subcutaneously distributed over three spots on the flank. 7-10 d after immunization, the inguinal, brachial, and axillary lymph nodes were removed from sensitized donors, and single-cell suspensions were prepared. The cells were adjusted to 8 x 106/ml in complete DMEM containing 15-20 #g/ml of the appropriate peptide and incubated at 37~ in a humidified atmosphere containing 5% CO2. 4 d later, the cells were washed twice with buffered saline solution, counted, resuspended in 50% PercoU (Pharmacia Biotech, Inc., Piscataway, NJ), and centrifuged at 1,500 rpm for 15 rain at room temperature. Lymphoblasts were removed from the gradient, washed, and injected intraperitoneally into naive mice. Clinical Evaluation. Mice were observed drily for clinical signs of disease. Mice were scored according to their clinical severity as follows: grade 0, no abnormality; grade 1, limp tail; grade 2, limp tail and hind limb weakness (waddling gait); grade 3, partial hind limb paralysis; grade 4, complete hind limb paralysis; and grade 5, moribund. The data are plotted as the mean daily clinical score for all animals in a particular treatment group. In some instances, the mean maximal clinical score per group is given as an indication of disease severity. A relapse was defined as an increase of at least one full grade in clinical score after the animal had previously improved at least a full clinical score and had stabilized.
Induction of R-EAE by

Histologic Evaluation. Mice were anesthetized with sodium pentobarbital and killed by total body perfusion through the left ventricle with chilled 3% glutaraldehyde in phosphate buffer, pH 7.3. Spinal cords were removed by dissection and cut into 1-mm-thick cross sections, which were postfixed in 1% OsO4, dehydrated, and embedded in Epon as previously described (29) . Toluidine bluestained sections from 10 to 11 segments per mouse were read blind and scored as follows: _+, mild inflammation without demydination; 1+, inflammation with focal demyelination; 2", inflammation with multiple loci of demyelination; 3% marked inflammation with bilateral, converging areas of demyelination; and 4 +, extensive bilateral areas of demyelination and remydination.
Ag-specific Delayed-type Hypersensitivit,/ (DTH). DTH responses
were quantitated using a 24-h ear swelling assay in mice challenged with 5 #g of the relevant Peptide (in 10/~1 saline) as previously described (30) . Results are expressed in units of 10 -4 inches + SEM. Ear swelling responses were the result of mononuclear cell infiltration and showed typical DTH kinetics (Le., minimal swelling at 4 h, maximal swelling at 24-48 h).
In Vitro T Cell Proliferation Assay. T cell proliferative responses
were assessed by incorporation of [3H]thymidine. 5 x 105 viable draining lymph node (brachial, axillary, and inguinal) cells recovered from immunized mice were cultured in 96-well flat-bottom microculture plates (Falcon Labware, Becton Dickinson and Co., Oxnard, CA) in 0.2 ml of DMEM (Gibco Laboratories, Grand Island, NY) supplemented with 0.75% syngeneic mouse serum. Alternatively, 5 x 10 s splenocytes from adoptive transfer recipients were cultured as described above. Triplicate cultures were stimulated with the indicated doses of antigen and incubated in a humidified atmosphere of 5% COs. After 72 h, culture wells were pulsed with 1.0/zCi of [3H]thymidine (6.7 Ci/mM, ICN Biomedicals, Inc., Costa Mesa, CA). Cultures were harvested 24 h later with a semiautomated cell harvester, and measurements of radioactive material were determined in a scintillation counter. 
Statistical Analyses. Comparisons of the percentage of animals
showing clinical disease between any two groups of mice were analyzed by chi-squared using Fisher's exact probability. Comparisons of the mean day of onset and mean maximal severity between any two groups of mice were analyzed by the Student's t test. P values <0.05 were considered significant.
Results
Evidence that PLP139-151 Is the Dominant Encephalitogenic PLP Epitope in SJL/J Mice. Data from our laboratory and from others have shown gain of T cell responses to additional myelin epitopes and switches in use of MHC class II I-A and I-E restriction elements during the course of EAE induced with intact MBP (13) (14) (15) 17) . To approach the possibility of similar switches in antigen specificity through the course of PLP-induced EAE, we first determined the relative contributions of T cell responses to the two immunodominant encephalitogenic PLP epitopes, PLP139-151 (5, 32) and , in R-EAE induced with intact PLP. As seen in Fig.  1 , mice receiving sham-coupled ceUs and subsequently primed with intact PLP (/1) underwent a normal relapsing-remitting disease course, with four out of seven (57%) of the mice exhibiting disease symptoms by day 17 after immunization. Sham-tolerized mice primed with PLP139-151/CFA (B) also underwent a relapsing disease course with 13/14 (93%) of the mice affected by day 14 after immunization. The reduced incidence and longer time of onset of PLP-induced vs PLP139-151-induced R-EAE may be due to lower molar concentrations of encephalitogenic epitopes in the whole PLP preparations. Prior tolerization with intact PLP resulted in total protection of the animals from both the initial and rdapsing episodes of PLP-induced clinical disease (,4) and PLP139-151-induced disease (data not shown). In contrast, although administration of PLP139-151-coupled splenocytes significantly delayed the onset of PLP-induced disease, four out of seven (57%) of these mice developed clinical disease between days 31 and 43 after immunization, and these animals experienced a much milder form of disease (mean maximal disease severity [MMS] = 1.0) as compared with the control group (MMS --2.5). Interestingly, the timing of clinical symptoms in the PLP139-151-tolerized group (31-43 d) was similar to that seen for the initial relapse in the control group (days 31-38 in three out of four mice). These results cannot be explained by differences in the ability of PLP and PLP139-151 to induce tolerance, since PLP139-151-coupled splenocytes effectively inhibited PLP139-151-induced R-EAE (B). We have previously demonstrated that tolerance induced by antigen-coupled syngeneic splenocytes is antigen specific (33) . Pretolerance with PLP inhibits the onset of PLP-induced dis-100 ease (A) but not MBP-induced R-EAE (34) . Collectively, these results indicate that the initial acute encephalitogenic response in PLP-immunized mice is directed primarily towards PLP139-10 151, and that this epitope is immunodominant when corn-"~ pared with , responses to which possibly contribute to later phases of disease in mice primed with the ~ intact, multideterminant PLP molecule.
Diversification of Proliferative Responses to PIP Epitopes during 1
the Course of Adoptive R-EAE Induced with PLP139-1Sl-specific T Cells. To examine directly the functional consequences of epitope spreading in the pathogenesis of relapsing EAE, we reasoned that the reliable relapsing-remitting disease induced by the major immunodominant PLP139-151 epitope would provide an ideal system, in that the initial acute disease would be mediated by T cells specific for a single encephalitogenic epitope. R-EAE was initiated by adoptive transfer of lymph node T cells specific for PLPD9-151, and responses to this epitope and to other non-cross-reactive encephalitogenic PLP (PLP178-191 [27] and PLP104-117 [35] ) and MBP (MBP84-104 [36] ) epitopes were assessed (Fig. 2) . On day 3 after transfer (before the appearance of acute EAE, MMS ---0) and on day 17 (concomitant with the peak of acute EAE, MMS = 3.5), splenic proliferative responses to PLP139-151, but not to the other PLP determinants or to MBP84-104, could be detected. However, on days 24 and 40 after transfer (during the remission from the acute disease episode), significant splenic proliferative responses were seen to both the inducing PLP139-151 epitope and to PLP178-191M, which further increased at day 60 after transfer (concomitant with the appearance of a clinical relapse in this group of mice, MMS = 4.0). The development of PLP178-191M-specific responses is reproducible in that it was noted in five separate experiments in mice with both active and adoptive PLP139-151-induced EAE (see also 
Peptide Specificity of T Cell Responses in SJL Mice Primed with Intact PLP, PLP139-151, and PLPI78-191M. PLP is a g
--, 276-amino acid structural myelin protein that is highly conserved across many species. The sequences of mouse, rat, and human PLP molecules are identical but differ from the bovine sequence at four positions, including an alanine for phenylalanine substitution at position 188 (37) . To determine the fine specificity of T cell responses to the dominant and secondary PLP epitopes and to identify potential affects of the substitution at position 188 on T cell recognition of intact PLP, proliferative assays were performed on PLP, PLP139-151, and PLP178-191M-primed lymph node cells (Fig. 3) . Before the onset of acute clinical symptoms (10 d after immunization), lymph node T cells from SJL/J mice primed with intact bovine PLP responded well to PLP139-151 and 
Intermolecular Epitope Spreading in MBP84-104-induced R-EAE.
To determine if epitope spreading could be identified in a second peptide-induced model of R-EAE, disease was induced in SJL/J mice by the transfer of MBP84-104-specific T cells. Individually, these animals generally display a milder acute disease course than recipients of PLP139-151-specifir T cells and an initial relapse that was more severe than the acute disease (Fig. 4 A) . T cell reactivity, as measured by DTH in vivo (Fig. 4 B) and by T cell proliferation in vitro (not shown), to the immunodominant PLP139-151 epitope developed in these mice concomitant with the appearance of the first relapse. This has been a consistent observation in a number of experiments and is an example of intermolecular epitope spreading. The more severe relapse in these mice concurrent with the development ofT cell reactivity to PLP139-151 is consistent with our earlier observation that this peptide is overwhelmingly the dominant encephalitogenic myelin epitope in the SJL/J mouse (38) .
Functional Evidence that PLP178-191M-specific Splenic T Cells from Mice with PLP139-151-induced R-EAE Participate in Relapsing Pathology.
To further delineate the encephalitogenic potential of recruited T cells with specificity for endogenous neuroepitopes, we asked if PLP178-191M-specific T cells from mice with R-EAE induced by PLP139-151 were capable of transferring EAE (Table 1) (Fig. 1) or transfer disease to naive recipients (Table 1) . Collectively, these results suggest that PLP178-191M-specific Thl cells are activated by recognition of the endogenous mouse PLP178-191 epitope during the course of both active and adoptive PLP139-151-induced R-EAE, and that these cells are most likely involved in the relapsing course of disease, as they have potent encephalitogenic activity. The data in Fig. 1 indicated that responses to secondary PLP epitopes, including PLP178-191, played a role in the later phases of PLP-induced R-EAE. As a second functional test of the role of epitope spreading in the relapsing pathology of PLP139-151-induced R-EAE, we asked if tolerance to intact PLP induced after the acute phase of disease would be able to ameliorate clinical relapses. Thus, R-EAE was induced in SJL/J mice by active immunization with PLP139-151 in CFA. After recovery from the acute phase of disease (day 19 after priming), 12-13 mice were each tolerized by the intravenous injection of syngeneic splenocytes coupled with intact PLP and observed for an additional 50 d for the development of clinical relapses. As seen in Fig. 5 , thirteen out of thirteen (100%) of the sham-tolerized mice exhibited clinical relapses during the observation period, but only five out of twelve (42%) of the PLP-tolerized mice relapsed, and these relapses were routinely mild (increase of only one clinical grade) as compared with those in the sham-tolerized group (increases of two or more clinical grades). Similar results were observed when mice were tolerized with a crude mouse spinal cord homogenate that contains a heterogeneous mixture of neuroantigens (data not shown). Since tolerization with intact PLP inhibits T cell responses to both PLP139-151 and PLP178-191 ( Fig. 1 and additional data not shown) and has no effect on induction of active EAE induced with intact MBP (34), these results are consistent with a role for PLP178-191-specific responses, but a lack of MBP84-104-specific responses, in PLP139-151-induced R.-EAE.
Peptide-specific Tolerance Prevents the Development of Epitope
Spreading. Based on the temporal sequence of appearance of PLP178-191M responses (Fig. 2) , the data to this point are consistent with the hypothesis that T cells with novel specifldties are activated after CNS tissue damage has occurred. One would thus predict that inhibition of CNS damage may prevent priming of T cells with specificity for endogenous self epitopes. Therefore, we asked if induction of PLP139-151-specific tolerance after effector cell transfer but before the onset of the initial acute clinical episode of adoptive PLP139-151-induced1 R-EAE would prevent the development of T cell reactivity to the PLP178-191M epitope. The intravenous injection of PLP139-151-splenocytes (SP) on day 3 after adoptive transfer of PLP139-151-activated lymph node cells resulted in a significant diminution of clinical R-EAE (Fig.  6 A) . In addition, these animals were tested for DTH responsiveness to both the inducing PLP139-151 epitope and to PLP178-191M on day 25 after transfer. As seen in Fig. 6 B, the four sham-SP-treated mice that developed a severe acute phase ofEAE (MMS = 4.5) displayed significant DTH upon challenge with either PLP139-151 or PLP178-191M, indicating that epitope spreading can also be demonstrated by DTH, an in vivo readout of proinflammatory cytokine activity. The three out of six mice in the PLP139-151-tolerized group that developed very mild EAE (MMS = 1.0) also displayed DTH responses to both peptides that were significantly above background, but significantly less than those observed in the sham SP-treated mice. In contrast, the three tolerant mice that displayed no acute clinical disease symptoms did not respond to either the inducing peptide or to PLP178-191M. Pathological examination of these groups of animals was also performed (Fig. 7) . The sham-tolerized mice showed the characteristic changes of EAE, consisting of florid mononuclear cell infiltrations in meninges and around parenchymal venules in the white matter columns of the spinal cord. Tolerized mice that displayed mild neurological impairment showed 80 Epitope Spreading in Relapsing Experimental Autoimmune Encephalomyelitis very minimal tissue involvement, consisting mainly of meningeal inflammatory infiltrates. Occasionally, one could observe a focal demyelinating lesion that remained confined to the immediate sub-pial layer of the white matter. In contrast, the tolerized animals that showed no clinical symptoms were devoid of any CNS lesions. These results indicate that the diversification of the immune response normally seen in mice with R-EAE correlates with the severity of both clinical and histological symptoms during the acute phase of disease. Most importantly, epitope spreading can be abrogated by induction of specific tolerance to the inducing epitope before acute tissue damage.
Discussion
Using antigen-specific, peripherally induced immunologic tolerance as a probe for analysis of the neuropathologic T cell repertoire, we have previously shown that PLP, not MBP, constitutes the immunodominant neuroantigenic myelin protein for the induction of R-EAE in the SJL/J mouse (23) . Residues 139-151 and 178-191 of the PLP molecule have been previously described as being codominant encephalitogenic epitopes (27, 32) . However, our examination of the contributions of T cell responses to these two PLP determinants revealed that the majority of immunopathologic reactivity during the acute phase of R-EAE in SJL/J mice primed with the intact PLP molecule is directed at the PLP139-151 epitope (Fig. 1) . Thus, the current findings indicate that PLP139-151 is the dominant immunopathologic epitope of the PLP molecule in acute disease and suggest that responses to secondary PLP determinants, primarily to PLP178-191, may contribute to the later phases of disease in mice primed with the multideterminant PLP molecule. These results are similar to recent findings in the Lewis rat acute EAE system, where it has been shown that responses to a secondary enceph'alitogenic epitope (MBP87-99) arise considerably later than responses to the dominant MBP68-86 epitope (39) , and that MBP-induced clinical disease is more efficiently regulated upon tolerization with intact MBP than with the dominant MBP68-86 peptide (40, 41) .
The immunodominance of PLP139-151 is also illustrated by the fact that active EAE can be induced by immunization with this peptide emulsified in CFA (5), whereas induction of active EAE with PLP178-191 requires the additional use of pertussis toxin (27) . In addition, the clinical course of both active and adoptive PLP139-151-induced K-EAE is characterized by a severe acute clinical disease phase and multiple clinical relapses (Figs. 1 and 5) , whereas PLP178-191M-induced disease is characterized by a relatively mild acute phase (Table  1 and additional data not shown). Lastly, analysis of proliferative responses in SJL/J mice primed with intact PLP has revealed that precursor frequency of PLP139-151-specific T cells is three-to fourfold higher than the frequency of PLP178-191-specific cells (McRae, B. L., K. M. Nikcevich, and S. D. Miller, manuscript in preparation). This is mirrored by the increased bulk of proliferative responses observed upon challenge of PLP-primed cells with PLP139-151 (Fig. 3) .
T cell specificities appear to change during the course of R-EAE (12) (13) (14) (15) 42) , and this may also occur in MS. Clearly, the expression of these additional reactivities could be due to the activation of T cells specific for endogenous myelin epitopes released during the acute phase of CNS damage. Although some of the specificities that arise have been shown to encompass determinants previously defined as encephalitogenic when administered with complete adjuvant, the significance of these events in disease progression (i.e., whether T cells spedfic for these recruited epitopes contribute to the immunopathology of relapsing disease) is largely unknown.
To determine directly if new antigen specificities arise during the course of R-EAE, we used a model of relapsing EAE wherein disease was initiated, either actively or adoptively, by T cells specific for the immunodominant PLPD9-151 epitope. T cell reactivity to other reported encephalitogenic PLP epitopes and to the major encephalitogenic epitope of MBP (MBP84-104) was then assessed. After the initial acute phase 
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Epitope Spreading in Relapsing Experimental Autoimmune Encephalomyelitis of disease (days 24, 40, and 60), significant proliferative (Fig.  2 ) and DTH responses (Fig. 6) to the subdominant PLP178-191M epitope were detected. Several observations indicate that this response is due to the activation of endogenous host T cells. First, there is no cross-reactivity observed at the clonal (data not shown) or polyclonal T cell levels (Fig. 3) between PLP139-151 and PLP178-191M, indicating that the response is not due to the transferred effector cell population. Second, this response is specific for the mouse 178-191 sequence, since the cells from mice with disease initiated by PLP139-151 do not respond to bovine sequence (PLP178-191B), which contains an alanine for phenylalanine substitution at position 188. Lastly, the induction of PLP139-151-specific tolerance in recipients of PLP139-151-activated T cells prevents clinical disease and the induction of DTH reactivity to PLP178-191M (Fig. 6 ), indicating that CNS tissue damage must precede the development of the recruited response. Interestingly, the histopathological severity of the acute phase of PLP139-151-induced clinical disease roughly correlated with the magnitude of the DTH response to PLP178-191M observed 25 d after disease initiation (Fig. 6 ). Our ability to prevent epitope spreading by tolerizing to the initiating epitope confirms recent findings that induction of tolerance to glutamate decarboxylase before the onset of insulitis in nonobese diabetic mice prevents the development of diabetes and the accompanying immune responses to other pancreatic fl cell antigens such as carboxypeptidase H, insulin, and Hsp65 (17, 18) . Descriptions of epitope spreading in EAE have largely involved descriptions of additional proliferative specificities of T cells from various lymphoid compartments in mice undergoing EAE induced by intact MBP (12-14) or an encephalitogenic MBP peptide (24) . However, it is possible that the emergence of new specificities during R-EAE may simply be secondary events in disease progression that do not influence the pathology or clinical expression of disease. For example, T cell lines and clones that proliferate to defined encephalitogenic epitopes but do not mediate tissue destruction upon transfer to naive recipients, presumably because of lack of production of proinflammatory cytokines such as lymphotoxin (43) , have been described. The only functional evidence to date that T cells specific for secondary epitopes might contribute to clinical relapses comes from tolerance studies showing that, after recovery from MBP-induced R-EAE, tolerization with mouse spinal cord homogenate (containing a heterogeneous mixture of neuroantigens) only, but not with MBP, provided an effective means of inhibiting the subsequent clinical relapses (15, 33) . These studies provide a direct functional indication that the response to that particular myelin protein or epitope contributes to disease pathology. The involvement of intermolecular epitope spreading in SJL/J mice with R-EAE induced by immunization with MBP84-104 is supported directly by the present observation that PLP139-151-specific responses appear to contribute to the initial severe clinical relapse seen in this disease model (Fig. 4) .
In the current study, we took direct approaches to the question of the clinical significance of the development of the PLP178-191M-specific T cells in mice with PLP139-151-induced R-EAE. First, we showed that PLP178-191M-reactive cells recovered from the spleens, but not the peripheral lymph nodes (data not shown), of mice 40-50 d after transfer of PLP139-151-specific T cells or active immunization with PLP139-151 mediate EAE after in vitro activation and transfer to naive recipients (Table 1) . It is also significant that PLP178-191M-specific responses occurred after both active and adoptive induction of disease, indicating that prolonged peripheral antigenic stimulus from a bolus of PLP139-151/CFA is not necessary to invoke epitope spreading. A second functional test of the role of epitope spreading in the relapsing pathology of PLP139-151-induced K-EAE involved the demonstration that tolerance induction to determinants within the PLP molecule alone after the acute phase of disease was sufficient to ameliorate clinical relapses (Fig. 5) . Taken together with the data shown in Figs. 1 and 2 , these results are compatible with a model wherein responses to PLP178-191 and possibly to other secondary or cryptic PLP epitopes (intramolecular epitope spreading), but not to the MBP84-104 epitope (intermolecular epitope spreading), contribute to the relapsing pathology of K-EAE induced with the immunodominant PLP139-151 peptide.
Collectively, the results demonstrate that new T cell specificities to epitopes on the same and/or different myelin proteins emerge after acute CNS damage in SJL/J mice with peptide-induced K-EAE and are capable of mediating clinical disease. It is possible that local CNS presentation of endogenous neuroepitopes after acute CNS damage could be mediated by infiltrating inflammatory macrophages or by endothelial cells and/or astrocytes that have been shown to up-regulate expression of MHC class II (10, 44), certain adhesion molecules (45) , and B-7 costimulatory molecules (Nikcevich, K. M., J. A. Bluestone, and S. D. Miller, manuscript in preparation) in response to proinflammatory cytokines. Alternatively, Mamula et al. (46) recently demonstrated that activated B cells can present multiple determinants from a single protein in an immunogenic form to overcome T cell tolerance. Antigen presentation by B cells has been postulated to be important in the pathogenesis of SLE, in which T cell-dependent IgG1 autoantibodies are produced against small nuclear ribonucleoproteins (46, 47) . Although B cells are not necessary for the transfer of K-EAE (48), the role of activated B cells in diversification of autoimmune responses by presenting antigen to naive T cells is yet to be determined. It is interesting to speculate that epitope spreading may play a role in the pathogenesis of chronic and/or relapsing-remitting human autoimmune diseases such as SLE, rheumatoid arthritis, and MS. In MS, responses to a broad spectrum of myelin proteins could occur as a result of CNS damage initiated by T cell reactivity against a CNS-resident pathogen (22) or by a cross-reactive response between a pathogenencoded epitope and an epitope on a neuroantigen (16, 23) . Regardless of the initiating event, the current findings have important implications for designing effective antigen-specific immunotherapies for treatment of chronic autoimmune disorders.
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